Filing Details
- Accession Number:
- 0001447362-24-000123
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-08-05 16:16:30
- Reporting Period:
- 2024-08-01
- Accepted Time:
- 2024-08-05 16:16:30
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1447362 | Castle Biosciences Inc | CSTL | Services-Medical Laboratories (8071) | 770701774 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1856565 | M Kristen Oelschlager | C/O Castle Biosciences, Inc. 505 S Friendswood Drive, Suite 401 Friendswood TX 77546 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-08-01 | 8,764 | $22.72 | 137,061 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-08-01 | 4,225 | $23.77 | 132,836 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Kristen Oelschlager on March 15, 2024.
- This transaction was executed in multiple trades at prices ranging from $22.14 to $23.13, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $23.23 to $24.09, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.